Project Grant P01AI165066
Award Date
9/22/22
Completion Date
8/31/25
Dollars Obligated
$5.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This three-year, $18.13 million project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at the University of Washington and five sub-awardee institutions to develop broadly protective coronavirus vaccines. Under the Allergy and Infectious Diseases Research program, the grantee and sub-awardees will pursue three outputs: tools to study coronaviruses, antibodies for treatment, and vaccine candidates. They will generate reverse...
This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $755,225 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Loyola University of Chicago to develop a novel pan-coronavirus vaccine. The goal is to create a vaccine targeting conserved coronavirus antigens (S2, M, and N proteins) from both the Sarbecovirus and Merbecovirus lineages, in order to provide broad protection against future emerging pandemic coronaviruses. The project will...
The Wistar Institute Of Anatomy And Biology was awarded a three-year, $3,232,020 Project Grant from the Department of Health and Human Services National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will support research aimed at modulating epitope immunodominance and tracking B-cell antigen interactions to inform vaccine design against rapidly mutating viruses. Specifically, the grantee will develop novel strategies to...
This $2,178,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a "tunable nanophage platform" for rapid vaccine design and screening against emerging infectious disease threats. The key objectives are to engineer "second generation" nanophage particles that can display the spike receptor binding domains of SARS-CoV-2 and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $247,750 R21 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Maryland, Baltimore. The grant supports structural investigations of the coronavirus spike (S) protein, which is the key immunogen in COVID-19 vaccines. The research aims to provide unprecedented insights into how N-glycan maturation during S protein secretory trafficking modulates its conformations...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is focused on developing a pioneering class of nanobodies (NB) to provide comprehensive protection against beta-coronaviruses, including SARS-CoV-1, MERS-CoV, and SARS-CoV-2. The $867,563 award to Rockefeller University aims to identify, isolate, and characterize a diverse repertoire of highly potent and broadly...
The University of Washington received a $41,075,241 Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award is for a project titled "Machine Learning-Enabled Design of Prototype Pathogen Vaccines and Antibodies" and will run from August 2024 to July 2027. The project aims to develop end-to-end strategies for pandemic preparedness vaccine development, focusing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,942 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Georgia Tech Research Corporation (Georgia Tech) for a project titled "Self Assembled Peptide Nanoparticles as Multi-Antigen Universal Influenza Vaccines." The goal of this 5-year project is to develop a universal influenza vaccine using self-assembled protein nanoparticles that present multiple conserved influenza...
The University of California, Irvine (UCI) was awarded a $33,116,067 Cooperative Agreement from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to conduct basic and translational research to develop prototype vaccines against emerging viruses using two universal, programmable vaccine platforms: adjuvanted recombinant protein (ARP) and mRNA/lipid nanoparticle (LNP) vaccines. The research...